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Abstract. The emergence of artemisinin resistance among Plasmodium falciparum in the Greater Mekong subregion
threatens malaria control interventions and is associated with multiple unique mutations in K13 (PF3D7_1343700). The
aim of this study was to survey Cambodian Plasmodium vivax for mutations in the K13 ortholog (K12, PVX_083080)
that might similarly confer artemisinin resistance. Extracted DNA from Cambodian isolates collected between 2009
and 2012 was pooled by province and year and submitted for next-generation sequencing. Single-nucleotide polymor-
phisms (SNPs) were identified using a pile-up approach that detected minority SNPs. Among the 14 pools, we found six
unique SNPs, including three nonsynonymous SNPs, across six codons in K12. However, none of the SNPs were ortho-
logous to artemisinin resistance–conferring mutations in PF3D7_1343700, and nonsynonymous changes did not persist
through time within populations. These results suggest a lack of selection in the P. vivax population in Cambodia due
to artemisinin drug pressure.
Multiple reports of artemisinin resistance in Plasmodium
falciparum have come from Cambodia and the Thai–Burmese
border.1–5 A molecular correlate of this resistance was
recently discovered, and resistance was found to be associated
with specific mutations in theBTB/POZ and propeller domains
of the P. falciparum kelch protein, K13 (PF3D7_1343700).6–10
K13 mutations are now being used as molecular markers
for surveillance of artemisinin resistance.9,10
Artemisinin resistance has not been reported in Plasmodium
vivax.3,11 However, in Cambodia, antimalarial drugs are often
dispensed without species-level diagnosis, and coinfections are
common, likely resulting in artemisinin exposure to P. vivax.
Moreover, dihydroartemisinin–piperaquine replaced chloro-
quine for treatment of P. vivax malaria in Cambodia in
2012 due to concerns of chloroquine resistance. Resistance-
conferring mutations to antimalarial drugs in both P.
falciparum and P. vivax have previously been described for
several orthologous genes.12–14 This historical pattern sug-
gests that surveillance of mutations in the orthologous gene
to K13 among P. vivax (K12, PVX_083080) in Cambodia is
warranted. In the case of falciparum malaria, mutations in
K13 existed in the population before widespread artemisinin-
based combination therapies (ACTs) use. Thus, as ACTs are
increasingly used to treat P. vivax, a baseline evaluation of
K12 mutations and a means of rapid surveillance for potential
resistance mutations is needed.5,6,11,12
The aim of this study was to develop a rapid method to
survey K12 for mutations that might confer artemisinin
resistance and conduct a baseline evaluation of the reser-
voir of genetic diversity in K12. We modified our previ-
ously described pooled next-generation sequencing (NGS)
approach and validated it using controls and simulations.15
NGS can reliably detect single-nucleotide polymorphisms
(SNPs) in minority strains from complex infections that
can otherwise be overlooked by traditional molecular–
epidemiological methods, which often rely on Sanger
sequencing.16 As such, previous surveillance of the P. vivax
K12 gene may have overlooked minority strain polymor-
phisms and missed emerging resistance at low frequency
in the population.17 In addition, using an NGS with pooled
clinical isolates has proven to be accurate, sensitive, and
cost-effective as compared with Sanger sequencing.15,16
Whole blood from 304 patients presenting with uncompli-
cated P. vivax malaria to seven clinical sites throughout west-
ern and northern Cambodia were collected from 2009 to
2012 by the Armed Forces Research Institute of Medical
Science (Study Protocol WR1576). The study was approved
by the Walter Reed Army Institute of Research Institutional
Review Board (IRB), the Cambodian National Ethics Com-
mittee for Health Research and the Biomedical IRB at Uni-
versity of North Carolina. All participants provided written
informed consent before sample collection.
DNA was extracted from individual samples and pooled
in an isovolumetric manner by province and year to create
14 pools (Figure 1 and Supplemental Figure 1). Two addi-
tional samples containing DNA extracted from a monoclonal
monkey-adapted P. vivax infection were sequenced as con-
trols. Polymerase chain reaction (PCR) used the FastStart
High Fidelity PCR System (Roche, Mannheim, Germany).
A 2,139-bp fragment encompassing the entire K12 gene was
amplified using primers Pv.kelch-447706-G-Fwd (GAAAGC
TGCCAAGGGAAGTA) and Pv.kelch-449945-G-Rev (CTC
CCCATCTGTTCCATGTC). In 50 μL PCR reactions,
0.5 μL of Roche FastStart Hi-Fidelity Taq, 400 nM of for-
ward and reverse primers, 200 nM of deoxynucleoside tri-
phosphates, 2.25 mM of MgCl2, 5 μL of 10X reaction buffer,
and 4 μL of template were used. Amplification cycling condi-
tions included 95°C for 3 minutes, 16 cycles at 95°C for
20 seconds, a 20-second annealing step ranging from 70°C to
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63°C with a ΔT of 1°C per two cycles, and an extension of
72°C for 3 minutes. This was followed by 24 cycles of 95°C
for 20 seconds, 63°C for 20 seconds, and an extension
of 72°C for 3 minutes, and a final extension of 72°C for
5 minute. PCR products were purified using the Invitrogen
PureLink® PCR Purification Kit (ThermoFisher Scientific,
Chicago, IL) and sheared on a Covaris S2 instrument
(Woburn, MA) to an average fragment size of 350 bps.
Sheared amplicons were prepared with the Ion Plus Frag-
ment Library Kit and Ion Xpress Barcode Adaptors (Life
Technologies, ThermoFisher Scientific, Chicago, IL) and
submitted to the Ion Torrent Personal Genome Machine®
Ion 318™ Chip with 400-base chemistry (ThermoFisher Scien-
tific, Chicago, IL).
Sequencing reads were aligned using Bowtie2 with default
settings to the P. vivax Sal-1 reference strain (v3; http://www
.plasmodb.org, accessed March 28, 2016), and the minor
allele frequency (MAF) at all positions across the amplicon
was determined using a revised version of our previously
described Minor Allele Catcher (MAC).15,18 The revised
MAC (rMAC) was rewritten in C++ and modified to
account for homopolymer errors common with Ion Torrent,
which could result in reduced detection of alleles or result
in false-positive alleles at low frequency. Bases and reads
were excluded from analysis if they had a mapping quality
less than or equal to 10, a read length less than or equal to
200 bp, a base quality of less than or equal to 20, a base
depth of less than or equal to 5,000, if SNPs occurred in the
first or last 25 bases of a read, or if 30% or fewer of the
reads were on the forward or reverse strand. Plots were gen-
erated with the R statistical packages dplyr, tidyr, ggplot2,
ggmap, easyGgplot2, rgdal, sp, and maptools.19
From the 14 P. vivax pools (Figure 1), we obtained a total
of 3,650,121 reads, of which 2,376,860 passed quality filters
and were included in the analysis. In our two control sam-
ples, we generated 448,139 reads of which 329,624 reads
passed quality filters and were included in the analysis. Over-
all, we achieved at least 5,000-fold coverage on ≥ 91% of
the nucleotide positions analyzed (Supplemental Figure 2).
A conservative MAF cutoff of 1.0% for SNP discovery was
chosen based on our previous work and the two control sam-
ples, which would predict < 1 false-positive SNP across all of
the samples.15
To validate the rMAC, we used a combination of simula-
tions and monoclonal control samples, as few clonal lines
were available for creating mixtures to empirically justify our
1% cutoff. The rMAC detected no SNPs in the two control
samples. We then simulated read libraries for each of our
unique mutations (three private alleles; three shared alleles)
with MAF varying at 0.25%, 0.5%, 1%, 2%, 5%, 10%, 20%,
and 30%, respectively. Reads were simulated to include com-
mon PCR and sequencing errors.20 These reads were then
subjected to the same analysis as the clinical and control
samples. The rMAC was able to identify simulated SNPs
as low as 0.25% in 12/13 simulated pools, failing to detect
G23E in the 0.25% simulation. Across different simulated
allele frequencies, we saw a high degree of correlation
between expected and observed values (r2 = 0.98) (Figure 2),
supporting our conservative cutoff of a 1% MAF.
Among the 14 pools, we found 12 SNPs across six codons.
Of these, three were nonsynonymous mutations (Table 1).
Three mutations were identified as private alleles, while the
others were shared between two or more pools. Two synony-
mous mutations persisted through time: I248I in the KP pop-
ulation and I340I in the PL population. The V552I mutation
shared between the OM2011 and KS2011 pools has been
previously reported in Ratanakiri Province among samples
collected in 2013.17 The highest MAF detected in this study
was 8.80% from the OM region in 2010. Most mutations
FIGURE 1. Pooling strategy of clinical isolates by province and year included in the study. Each pool is represented by a box with the number
of isolates pooled noted within the box.
FIGURE 2. Detection of simulated minor allele frequency (MAF)
using the revised Minor Allele Catcher (rMAC) pipeline. Reads
were simulated with mutations that matched our observed single-
nucleotide polymorphisms (Table 1) at frequencies of 30%, 20%,
10%, 5%, 2%, 1%, 0.5%, and 0.25%, respectively. Polymerase chain
reaction (PCR) error was simulated using an in-house script that
incorporated the effects of starting template amount and polymerase
error rates. It propagates polymerase errors such that early round
errors appear at a higher frequency than errors in latter rounds.
PCR-simulated sequences were then fragmented with read length
distribution similar to patient samples and processed with 454Sim to
incorporate sequencing errors similar to Ion Torrent sequencing.
The scatter plot shows a distribution of the observed simulated fre-
quencies calculated by the rMAC (observed frequency) vs. the eight
expected MAFs ranging from 0.25% to 30% (expected frequency).
A line of ideal fit (y = 1x + 0; colored gray) and a linear regressed
line of best fit (y = 1.04x + 0.003, r2 = 0.98; colored black) are over-
lain on the plot. Simulations were run with 11,745–191,130 starting
template copies, depending on the pooled sample and a polymerase
error rate of 3.5 × 10−6.
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were confined to the BTB/POZ domain or the fifth blade
of the kelch propeller domain of the K12 gene product and
were found at low frequencies (1–4%). None of the observed
mutations were in orthologous locations to artemisinin
resistance–conferring mutations in PF3D7_1343700.9
These results suggest that P. vivax contains a repertoire
of standing variation within the K12 gene, but no evidence
of resistance-conferring mutations before 2013. We would
expect K12 mutations that confer resistance would be under
directional selection and increase in frequency over time
given enough ACT drug use. Previous studies have found a
similarly low number of mutations in the K12 gene among
Cambodian P. vivax (2/284 clinical isolates).15,17 This stand-
ing variation in K12 is similar to the current understanding
of K13 mutations in African falciparum populations.9,15
We have developed and validated a rapid pooled NGS
approach for surveillance of K12 mutations. Although we
found only a small number of ephemeral nonsynonymous
mutations, our results show that pooled NGS surveillance for
allele frequency assessment may provide a more complete
picture of gene diversity than traditional Sanger sequencing
methods.17 In addition, this study provides a baseline to mea-
sure future changes to the P. vivax K12. Cambodia’s recent
shift to dihydroartemisinin–piperaquine as first-line therapy
for vivax malaria in 2012 will result in strong selective
pressure on the parasite and may eventually result in selec-
tion of mutations in this gene.11,12 Future surveillance of
the K12 gene with NGS techniques is warranted to capture
any potential homologous artemisinin resistance–conferring
mutations among P. vivax.
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